An Open-label Study With Maintenance Dosing of ORKA-002 in Participants With Moderate-to-Severe Plaque Psoriasis
Study sponsor: Oruka Therapeutics, Inc. · ORKA
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2029-07-01Estimated
Enrollment · participants160Estimated
Source updated2026-11-12Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.